Epiretinal membrane formation associated with letrozole therapy – Two case reports

Abstract

Letrozole, an aromatase inhibitor, is being increasingly used for adjuvant endocrine therapy in hormone-positive postmenopausal breast cancer. Although aromatase inhibitors are thought to increase vitreoretinal traction by causing estrogen reduction, posterior segment complications of letrozole are sparsely reported. We report two cases of presumed epiretinal membrane formation in postmenopausal, hormone receptor–positive breast cancer patients on adjuvant letrozole therapy.